Profiling of hepatic clearance pathways of Pittsburgh compound B and human liver cytochrome p450 phenotyping.

about

Profiling of hepatic clearance pathways of Pittsburgh compound B and human liver cytochrome p450 phenotyping.

Item

http://www.wikidata.org/entity/Q36690141

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Profiling of hepatic clearance ...... r cytochrome p450 phenotyping.

@ast

Profiling of hepatic clearance ...... r cytochrome p450 phenotyping.

@en

type

Item

label

Profiling of hepatic clearance ...... r cytochrome p450 phenotyping.

@ast

Profiling of hepatic clearance ...... r cytochrome p450 phenotyping.

@en

prefLabel

Profiling of hepatic clearance ...... r cytochrome p450 phenotyping.

@ast

Profiling of hepatic clearance ...... r cytochrome p450 phenotyping.

@en

P1476

Profiling of hepatic clearance ...... r cytochrome p450 phenotyping.

@en

P2093

Anne Van Vlaslaer

http://www.w3.org/2001/XMLSchema#string

Claire Mackie

http://www.w3.org/2001/XMLSchema#string

Mark E Schmidt

http://www.w3.org/2001/XMLSchema#string

Russell J Mortishire-Smith

http://www.w3.org/2001/XMLSchema#string

P2860

Accelerated throughput metabolic route screening in early drug discovery using high-resolution liquid chromatography/quadrupole time-of-flight mass spectrometry and automated data analysis.

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes.

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.

Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease.

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.

Disulfiram inhibits defluorination of (18)F-FCWAY, reduces bone radioactivity, and enhances visualization of radioligand binding to serotonin 5-HT1A receptors in human brain.

Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.

P2888

2191-219x-3-10

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/2191-219X-3-10

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Xavier Langlois

P577

2013-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1011571709

http://www.w3.org/2001/XMLSchema#string

P698

23406885

http://www.w3.org/2001/XMLSchema#string

P932

3599558

http://www.w3.org/2001/XMLSchema#string